Details

Autor(en) / Beteiligte

• Tassone, Pierfrancesco
• Neri, Paola
• Carrasco, Daniel R.
• Burger, Renate
• Goldmacher, Victor S.
• Fram, Robert
• Munshi, Vidit
• Shammas, Masood A.
• Catley, Laurence
• Jacob, Gary S.
• Venuta, Salvatore
• Anderson, Kenneth C.
• Munshi, Nikhil C.

Titel

A clinically relevant SCID-hu in vivo model of human multiple myeloma

Ist Teil von

• Blood, 2005-07, Vol.106 (2), p.713-716

Ort / Verlag

Washington, DC: Elsevier Inc

Erscheinungsjahr

2005

Quelle

MEDLINE

Beschreibungen/Notizen

• We developed a novel in vivo multiple myeloma (MM) model by engrafting the interleukin 6 (IL-6)-dependent human MM cell line INA-6 into severe combined immunodeficiency (SCID) mice previously given implants of a human fetal bone chip (SCID-hu mice). INA-6 cells require either exogenous human IL-6 (huIL-6) or bone marrow stromal cells (BMSCs) to proliferate in vitro. In this model, we monitored the in vivo growth of INA-6 cells stably transduced with a green fluorescent protein (GFP) gene (INA-6GFP+ cells). INA-6 MM cells engrafted in SCID-hu mice but not in SCID mice that had not been given implants of human fetal bone. The level of soluble human IL-6 receptor (shuIL-6R) in murine serum and fluorescence imaging of host animals were sensitive indicators of tumor growth. Dexamethasone as well as experimental drugs, such as Atiprimod and B-B4-DM1, were used to confirm the utility of the model for evaluation of anti-MM agents. We report that this model is highly reproducible and allows for evaluation of investigational drugs targeting IL-6-dependent MM cells in the human bone marrow (huBM) milieu. (Blood. 2005;106:713-716)